Alterations of serum cholinesterase in patients with gastric cancer

Gu, Shanzhi; Zhao, Xinhan; Quan, Ping; Li, Shengbin; Pan, Bo‐Rong

doi:10.3748/wjg.v11.i29.4604

Cited by 31 publications

(17 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, reductions in serum BChE can be found in various clinical conditions, such as injury, liver damage, infectious disease, and malnutrition [ 20 ]. During more recent years, a decrease in BChE could be observed in various malignancies [ 21 – 26 , 33 ]. The most important finding of our study was the association between low serum BChE levels and shorter PFS, CSS, and OS.…”

Section: Discussionmentioning

confidence: 99%

“…Moreover, decreased serum BChE levels have been observed in various clinical conditions, such as stress, chronic inflammation, and malnutrition [ 20 ]. In addition, low serum BChE levels seem to be indicative of advanced tumor stage and poor prognosis in various forms of cancer, including gastric [ 21 ], renal [ 22 ], upper urinary tract [ 23 ], prostate [ 24 ], and head and neck cancer [ 25 , 26 ]. In cervical cancer, two studies in small series of patients have reported on an association between low serum BChE levels and advanced tumor stage, and have suggested a correlation between the increase in serum BChE levels and a response to radiotherapy [ 25 , 27 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The value of pretreatment serum butyrylcholinesterase level as a novel prognostic biomarker in patients with cervical cancer treated with primary (chemo-)radiation therapy

et al. 2019

View full text Add to dashboard Cite

Background Deficiency in butyrylcholinesterase (BChE), a condition commonly noticed in liver damage, inflammation, and malnutrition, has previously been associated with impaired prognosis in different malignancies. The aim of the present study was to investigate the value of pretreatment serum BChE levels as a prognostic biomarker in patients with cervical cancer treated with primary (chemotherapy-[chemo-])radiation therapy. Methods We retrospectively evaluated data of a consecutive series of patients with cervical cancer treated with primary (chemo-)radiation therapy between 1998 and 2015. Pretreatment serum BChE levels were correlated with clinico-pathological parameters and response to treatment. Uni- and multivariate survival analyses were performed to assess the association between decreased serum BChE levels and progression-free (PFS), cancer-specific (CSS), and overall survival (OS). Results A total of 356 patients were eligible for inclusion into the present study. The median (IQR) pretreatment serum BChE level was 6180 (4990–7710) IU/l. Lower serum BChE levels were associated with lower BMI ( p < 0.001), advanced tumor stage ( p = 0.04), poor treatment response ( p = 0.002), the occurrence of disease recurrence ( p = 0.003), and the risk of death ( p < 0.001). In uni- and multivariate analyses, low pretreatment serum BChE levels were independently associated with shorter PFS (HR 1.8 [1.2–2.6]; p = 0.002), CSS (HR 2.2 [1.4–3.5], p < 0.001), and OS (HR 2.0 [1.4–2.9]; p < 0.001). Conclusions Low pretreatment serum BChE levels are associated with advanced tumor stage and poor response to treatment, and serve as an independent prognostic biomarker for shorter PFS, CSS, and OS in patients with cervical cancer treated with primary (chemo-)radiation therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

The value of pretreatment serum butyrylcholinesterase level as a novel prognostic biomarker in patients with cervical cancer treated with primary (chemo-)radiation therapy

et al. 2019

View full text Add to dashboard Cite

show abstract

“…In advanced liver cancer with or without hepatic involvement there is mild to moderate infl ammation and various degree of protein energy malnutrition resulting the level of pseudocholinesterase to decrease but in cirrhosis of liver pseudocholinesterase level would decrease very much when the number of functional parenchymal cells of liver decreases. Similarly in infective hepatitis the liver cells are damaged but hepatocytes are not decreased as compared to cirrhosis or carcinoma of liver 18,21 . Similar fi nding were also found by S Venkata Rao et al (2011) 21 and also by MG Khan (1962) 22 .…”

Section: Discussionmentioning

confidence: 99%

Pseudocholinesterase as a prognostic marker for liver disorder

Dhungana¹,

Sinha²,

Sapkota³

et al. 2015

J. Kathmandu Med. Coll.

View full text Add to dashboard Cite

Background: Liver is the main source of pseudocholinesterase. It is a non-specifi c cholinesterase found in the blood plasma and may be reduced in patients with advanced liver diseases. Measurement of serum pseudocholinesterase activity serves as a sensitive indicator of synthetic capacity of the liver and can be used as a prognostic marker for carcinoma. Objective: To study pseudocholinesterase activities in liver diseases. Method: A prospective study was conducted at College of Medical Sciences Teaching Hospital (CMS-TH), from May 2011 to May 2013 with 25 controls and 25 diagnosed cases each of carcinoma of liver, cirrhosis of liver, infective hepatitis and obstructive jaundice among both sexes of same age group attending medical outpatient and inpatient departments. Serum pseudocholinesterase and other liver function tests were performed with semi-autoanalyser and Roche Hitachi 902 respectively. Results: Pseudocholinesterase level was markedly decreased in carcinoma of liver (mean ± SD = 1369.48 ± 276.64 IU/L) followed by cirrhosis of liver (mean ± SD = 1735.16 ± 433.82 IU/L), infective hepatitis (mean ± SD = 3800.69 ± 764.17 IU/L), obstructive jaundice (mean ± SD = 5539 ± 791.05 IU/L) when compared with controls (mean ± SD = 6865.12 ± 928.41 IU/L). The difference in the means was statistically signifi cant (p <0.001). Conclusion:There was signifi cant decrease in pseudocholinesterase level in carcinoma of liver followed by cirrhosis of liver while less so in infective hepatitis. In obstructive jaundice the enzyme level was found to be decreased but higher than other liver diseases. The results indicated that with more severe liver cell destruction or cell degeneration, there was corresponding signifi cant decrease in the level of pseudocholinesterase, which could be used as diagnostic marker of liver disease.

show abstract

“…Systemic inflammation has been described to be associated with poor prognosis in a variety of malignancies [16]. Plasma BChE levels have been shown to decrease in advanced cancer patients with or without hepatic involvement, despite the other liver function tests yielding normal results [17]. One of the possible mechanisms for such BChE activity decrease in cancer patients could be secondary anorexia accompanying malignancy [18].…”

Section: Discussionmentioning

confidence: 99%

203 Preoperative butyrylcholinesterase level as an independent predictor of overall survival in clear cell renal cell carcinoma patients treated with nephrectomy

Iwamura¹,

Koie²,

Mikami³

et al. 2015

European Urology Supplements

View full text Add to dashboard Cite

The prognostic factors for the overall survival (OS) of clear cell renal cell carcinoma (ccRCC) patients treated with nephrectomy are not well defined. In the present study, we investigated the prognostic significance of preoperative butyrylcholinesterase (BChE) levels in 400 ccRCC patients undergoing radical or partial nephrectomy from 1992 to 2013 at our institution. Univariate and multivariate analyses were performed to determine the clinical factors associated with OS. Among the enrolled patients, 302 were diagnosed with organ-confined disease only (T1-2N0M0), 16 with lymph node metastases, and 56 with distant metastases. The median preoperative BChE level was 250 U/L (normal range, 168-470 U/L), and median follow-up period was 36 months. The 3-year OS rate in patients with preoperative BChE levels of ≥100 U/L was significantly higher than in those with levels of <100 U/L (89.3% versus 77.7%, = 0.004). On univariate analysis, performance status; anemia; hypoalbuminemia; preoperative levels of BChE, corrected calcium, and C-reactive protein; and distant metastasis status were significantly associated with OS. Multivariate analysis revealed that preoperative BChE levels and distant metastasis status were significantly associated with OS. Our findings suggest a possible role of preoperative BChE levels as an independent predictor of OS after nephrectomy in ccRCC patients.

show abstract

Alterations of serum cholinesterase in patients with gastric cancer

Abstract: Serum CHE activity has a close relation with the incidence of gastric cancer.

Cited by 31 publications

References 28 publications

The value of pretreatment serum butyrylcholinesterase level as a novel prognostic biomarker in patients with cervical cancer treated with primary (chemo-)radiation therapy

The value of pretreatment serum butyrylcholinesterase level as a novel prognostic biomarker in patients with cervical cancer treated with primary (chemo-)radiation therapy

Pseudocholinesterase as a prognostic marker for liver disorder

203 Preoperative butyrylcholinesterase level as an independent predictor of overall survival in clear cell renal cell carcinoma patients treated with nephrectomy

Contact Info

Product

Resources

About